CVS HEALTH Q3 2026 EARNINGS CONFERENCE CALL - CVS HEALTH CORP

Explicit Guidance:

• FY2026 Adjusted EPS: Raised to at least $8.20, an increase of $0.20 from the prior midpoint and >$1.00 above initial FY2026 expectations.
• FY2026 Revenue: Revised up to at least $420 billion.
• FY2026 Adjusted Operating Income (AOI):
  • Healthcare Benefits: $5.4 billion (up $200 million from prior midpoint).
  • Pharmacy & Consumer Wellness: At least $6.5 billion (up ~$1 billion, reflecting ~8% growth YoY).
  • Health Services: Reiterated at previously discussed levels.
  • Enterprise Total: At least $17.05 billion.
• FY2026 Cash Flow from Operations: Raised to at least $15.5 billion (an increase of >$5.5 billion over prior expectations), driven by working capital improvements.
• FY2026 Medical Benefit Ratio (MBR): Expected in the lower half of 89.5%–90.0% (range of 89.75% ±25 bps).
• FY2027 Adjusted EPS: Guidance set at a floor of $8.65, representing ~13% growth over the updated 2026 baseline; implies approximately mid-to-high single-digit EPS growth from 2026 to 2027.
• 2028 EPS CAGR: Expects to be in the high end of the mid-teens (14-16%) range.
• FY2027 Health Services AOI: Confirmed floor of at least $7.0 billion.
• FY2027 Pharmacy & Consumer Wellness AOI: Expects low single-digit growth off the $6.5 billion FY2026 baseline (third consecutive year of growth).
• Share Repurchases: Program to resume in Q4 2026.
• Dividends: Remains unchanged; nearly $2.6 billion returned to shareholders via dividends in YTD 2026.

Business-Segment Outlook:

• Healthcare Benefits (Aetna): Expecting another year of meaningful margin improvement in 2027 driven by disciplined underwriting, pricing, and medical cost management. Medicare Advantage business expected to show modest growth and "another year of nice margin expansion" in 2027, building on progress to return to target margins.
• Health Services (Caremark/Pharmacy Services):
  • 340B: Expects a year-over-year decline in 2027; business expected to largely stabilize by end of 2027.
  • Specialty Pharmacy: Continues to be a tailwind with expected strength.
  • Healthcare Delivery (Oak Street/Signify): Expects continued improvement in 2027, with Oak Street progressing toward profitability.
  • 2028 Selling Season: Confidence that 340B impacts will not spill into 2028; expects robust new business pipeline for the 2028 PBM season.
  • Trough Earnings: 2027 is expected to represent trough earnings for the segment ($7B floor), with a return to growth in 2028.
• Pharmacy & Consumer Wellness:
  • Rx Volume: Core pharmacy strength continues; same-store prescription volumes grew nearly 4% in Q3 2026.
  • GLP-1s: Prescription volumes for GLP-1s grew 23% in Q3 2026.
  • Outlook: Low single-digit AOI growth expected in 2027, driven by continued pharmacy strength and differentiated consumer offerings.

Market and Competitive Outlook:

• Medicare Advantage: Anticipates an elevated medical cost trend environment persisting into 2027, requiring continued disciplined pricing and risk management.
• PBM/Health Services: Navigating "transitory dynamics" in 340B; expects 2028 selling season to be "robust" with strong value proposition regarding affordability and transparency.
• Retail Pharmacy: Operating in an economically resilient sector; long-term prescription growth driven by medical innovation and demographics.
• Specialty Pharmacy: Growth driver due to the high cost of the 2% of population driving >50% of spend; focus on creating competition and affordability.

Macro / Industry Outlook:

• Regulatory (340B): Management does not expect the 340B program to go away fully but acknowledges current headwinds will resolve, with the program expected to stabilize by late 2027.
• Healthcare Trends: Acknowledges high single-to-low double-digit spending increases from health systems and drug manufacturers, creating an opportunity for the remaining CVS Health entity to tackle affordability and access.
• Aetna Performance: Medicare Advantage book is on a "multi-year journey" but is ahead of schedule, with the business moving into profitable territory in 2026.
• Medicare Policy: Aetna has made adjustments to benefits, geography, product mix, and networks for the 2027 payment year to maintain margin expansion despite elevated trends.

Strategic Initiatives:

• Corporate Separation: CVS Health will separate into two independent, publicly traded companies:
  • New CVS Health (RemainCo): Will include Aetna, Caremark, Pharmacy Services, Specialty Pharmacy, Oak Street, and Signify Health. Focus on integrated care for high-acuity populations (Medicare/Commercial/Medicaid) and affordability.
  • New CVS Pharmacy: Will include retail stores, mail order, MinuteClinic, and Health100. Focus on community health, technology, and consumer engagement.
• Timeline: Separation expected to be completed in the first half of 2028, subject to tax confirmation and customary conditions.
• Leadership: David Joyner to serve as Chairman/CEO of New CVS Health; Prem Shah to become CEO of New CVS Pharmacy.
• Financial Structure: Both companies targeted to have solid investment-grade balance sheets and strong free cash flow generation.
• Transaction Costs: One-time breakup costs contemplated within current guidance; run-rate costs expected to be manageable and offset by strategic value.
• Technology Integration: Health100 (AI-native platform) will serve as the "connective tissue" between the two independent entities via commercial agreements, rather than operational integration.
• Mail Order: To be retained within New CVS Pharmacy to ensure consumer-centric delivery models (90-day supply focus).

Risks and Headwinds to Outlook:

• Medical Cost Trends: Elevated trends in 2027 for Medicare and commercial plans may persist, requiring continued underwriting discipline.
• 340B Dynamics: Year-over-year revenue decline in 2027 due to 340B headwinds and health plan membership attrition (some attributed to strategic client decisions like Edna's PDP book).
• Consumer Dynamics: Potential impacts from consumer spending behavior affecting pharmacy wellness segments.
• Separation Complexity: Potential stranded costs, public company costs, and one-time breakup expenses (though deemed manageable).
• Regulatory Environment: Unspecified regulatory changes affecting Medicare Advantage pricing or PBM regulations.
• Market Volatility: FX or interest rate impacts not explicitly detailed but inherent in capital deployment planning.

Management Tone on the Future:

• Confidence Level: High; leadership explicitly states the separation is being executed from a "position of strength," citing eight consecutive quarters of "beat and raise," debt-to-leverage goals achieved ahead of schedule, and a $1.00+ EPS beat over initial 2026 expectations.
• Strategic Clarity: Management emphasizes "focus," "capital allocation," "agility," and "simplicity" as primary drivers, rejecting the notion that separation is necessitated by distress.
• Guidance Philosophy: Adheres to "credible targets," "disciplined execution," and maintaining a "prudent view of medical cost trends."
• Long-Term View: Confident in the ability to achieve the high-end of the mid-teens EPS CAGR through 2028.

Miscellaneous:

• Tax Status: The separation transaction is expected to be tax-free for U.S. federal income tax purposes.
• Shareholder Structure: Current CVS Health shareholders will own shares in both companies post-separation.
• Investor Relations: Updated guidance details and non-GAAP reconciliations available on the IR website and in the Q1 2027 10-Q.